BDO Wealth Advisors’s Cytokinetics CYTK Stock Holding History

BDO Wealth Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20	Closed	–	–	1129
2021 Q1	$0	Hold	20	–	–	﹤0.01%	1182
2020 Q4	$0	Hold	20	–	–	﹤0.01%	940
2020 Q3	$0	Buy	+20	New	+$468	﹤0.01%	886

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BDO Wealth Advisors's CYTK Position: Q2 2021 in Review

BDO Wealth Advisors sold out of Cytokinetics (CYTK) in Q2 2021, closing a stake of 20 shares.

BDO Wealth Advisors first reported a position in CYTK in Q3 2020 and held it in 3 quarters. The position peaked at $0 in Q1 2021. 190 funds tracked by Wall St. Rank hold CYTK as of Q2 2021.

BDO Wealth Advisors reported no remaining Cytokinetics position as of Q2 2021 after selling out during the quarter.
BDO Wealth Advisors sold 20 Cytokinetics shares in Q2 2021.
BDO Wealth Advisors first reported a position in Cytokinetics in Q3 2020 and held it in 3 quarters.
BDO Wealth Advisors's Cytokinetics position peaked at $0 in Q1 2021.
190 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2021.

Based on BDO Wealth Advisors's 13F filing for Q2 2021, filed 3 Sep 2021.